OCTAVE SPECIALTY GROUP, INC. (OSG) valuation

Bring your own price

Enter a share price and a discount rate — every multiple, the earning-power value and the reverse-DCF below recompute on the spot from OCTAVE SPECIALTY GROUP, INC.'s latest SEC EDGAR filings. Change either input and the whole page follows.

Share price (USD)

Discount rate (% per year)

Enter a share price to run the model.

The prefilled 8.9% is a plain CAPM cost of equity at β = 1: the 10-year Treasury yield (4.46%, 2026-06-18, U.S. Treasury 10-yr) plus the U.S. equity risk premium (4.46%, Damodaran 2026-01-01). Build a firmer per-company rate with the cost-of-equity and WACC calculators, then paste it here.

Share price — · awaiting your input

Market Capitalization

Equity value at your price

—

Price-to-Earnings

P/E · Trailing Diluted

—

Earnings Yield

EPS ÷ Price · Trailing

—

Price-to-Free-Cash-Flow

P/FCF · Trailing

—

Free-Cash-Flow Yield

FCF Yield · Trailing

—

Price-to-Sales

P/S · Trailing

—

Price-to-Book

P/B · Latest filing

—

Fundamentals from the filings

Every model input below comes straight from OCTAVE SPECIALTY GROUP, INC.'s SEC EDGAR XBRL filings — these are the denominators and bridge inputs the calculator pairs with your price and rate.

Trailing twelve months · TTM as of 2026-03-31 (Q1 FY2026)

Revenue: $174.8M
EBIT (GAAP): -$89.3M
EBIT margin: -51.1%
Operating cash flow: —
CapEx: —
D&A: $45.0M
Free cash flow: —
Stock-based comp: $12.1M
YoY revenue growth: 57.4%

Balance sheet · 10-Q · period ending 2026-03-31

Cash & equivalents: $93.5M
Total debt: $117.1M
Stockholders' equity: $712.6M
Preferred stock: $0
Excess cash: $93.5M

Total debt = Long-term debt ($117.1M) + Short-term borrowings ($0) .

Share count

Diluted shares (TSM-scaled): 45302.9M

Method: weighted-average diluted shares (no point-in-time count tagged). See the diluted-shares methodology for why this count denominates EPV/share and the reverse-DCF equity bridge.

Earning-Power-Value, reverse-DCF, and EV/EBITDA are hidden for this insurer. EPV and the reverse-DCF both anchor on an EBIT margin, but a insurer's "margin" is interest-spread × leverage with non-EBIT investment results mixed in; EV/EBITDA omits deposits and borrowings — the actual funding — so the multiple isn't interpretable. The trailing multiples above (P/E, P/S, P/B, P/FCF) still render, but the right lens here is price-to-tangible-book-value and ROE vs cost of equity — applied manually, outside this page.